BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30199306)

  • 1. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
    Abulkhair O; Al Balwi M; Makram O; Alsubaie L; Faris M; Shehata H; Hashim A; Arun B; Saadeddin A; Ibrahim E
    J Glob Oncol; 2018 Aug; 4():1-9. PubMed ID: 30199306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
    Bukamal Z; AlRayes A
    Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Jakimovska M; Maleva Kostovska I; Popovska-Jankovic K; Kubelka-Sabit K; Karadjozov M; Stojanovska L; Arsovski A; Smichkoska S; Lazarova E; Jakimovska Dimitrovska M; Plaseska-Karanfilska D
    Breast Cancer Res Treat; 2018 Apr; 168(3):745-753. PubMed ID: 29335924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
    El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
    Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.
    Bu R; Siraj AK; Al-Obaisi KA; Beg S; Al Hazmi M; Ajarim D; Tulbah A; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2016 Sep; 139(5):1091-7. PubMed ID: 27082205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
    Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    Dodova RI; Mitkova AV; Dacheva DR; Hadjo LB; Vlahova AI; -Hadjieva MST; Valev SS; Caulevska MM; Popova SD; Popov IE; Dikov TI; Sedloev TA; Ionkov AS; Timcheva KV; Christova SL; Kremensky IM; Mitev VI; Kaneva RP
    BMC Cancer; 2015 Jul; 15():523. PubMed ID: 26183948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
    Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
    Riahi A; Kharrat M; Ghourabi ME; Khomsi F; Gamoudi A; Lariani I; May AE; Rahal K; Chaabouni-Bouhamed H
    Clin Genet; 2015 Feb; 87(2):155-60. PubMed ID: 24372583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.